What did @kristinastout actually say?
The creator, identifying as a nurse practitioner affiliated with Harmony Wellness Clinic, showed herself injecting what she called a "maintenance dose" of tirzepatide, 2 mg (20 units) every two weeks. She said she uses it not for weight loss but because it "helps with inflammation," reduces "food noise," and improves her keratosis pilaris. She acknowledged this is a personal choice, not a requirement, and directed viewers to book appointments through her clinic.
She also mentioned trying to stop tirzepatide multiple times and feeling worse off it, though she said she did not regain weight. This is a real pattern some patients describe, but the way she framed it, as an inflammation and skin condition treatment, goes well beyond what tirzepatide is currently approved to do.
Does the science back this up?
Partially, and the parts that are supported are more tentative than she implied. The GLP-1 and GIP receptor agonist mechanism of tirzepatide does appear to have some anti-inflammatory effects, but calling it an inflammation treatment is a stretch right now.
On the inflammation angle: a 2023 paper by Ceriello et al. in Cardiovascular Diabetology noted that GLP-1 receptor agonists reduce circulating inflammatory markers like CRP and IL-6 in people with metabolic disease, largely as a downstream effect of fat loss and glucose normalization, not necessarily as a direct anti-inflammatory mechanism. Whether that applies at low maintenance doses in a non-obese, non-diabetic person is genuinely unknown.
The keratosis pilaris claim is even thinner. There is no published clinical evidence that tirzepatide improves KP. Anecdotal reports exist on forums, and some researchers speculate that reduced systemic inflammation could theoretically improve skin conditions linked to inflammation, but that is a long way from clinical evidence. She should not be presenting this as an established benefit.
Food noise reduction is the most evidence-adjacent claim. Friedrichsen et al. (2021, Diabetes, Obesity and Metabolism) showed GLP-1 agonists reduce reward-driven eating behavior, and the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) documented sustained appetite suppression with tirzepatide at standard doses. Whether a 2 mg every-other-week dose achieves pharmacologically meaningful GLP-1/GIP receptor engagement is not established.
What did they get wrong (or right)?
She got a few things right. Maintenance dosing as a concept is not invented. The SURMOUNT-5 and ongoing extension data suggest that some patients benefit from continued low-dose treatment to maintain outcomes. Her transparency about dosing and her personal use is more honest than many wellness-adjacent TikToks that imply vague benefits without disclosing any specifics.
What she got wrong is the framing. Describing tirzepatide as something that "helps with inflammation" as a standalone benefit, without qualifying that evidence is preliminary and largely observed in metabolic disease populations, is misleading. Listing keratosis pilaris as a benefit with zero clinical citation is a red flag. She presents personal experience as if it is generalizable clinical guidance, and she is directing viewers directly to book paid appointments with her. That is a conflict of interest she does not disclose.
The hashtag categorizing this as a "peptide" video also muddies the water. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist, not a research peptide. Grouping it with BPC-157 or TB-500 implies equivalency with unregulated compounds, which is inaccurate and potentially confusing for patients.
What should you actually know?
Tirzepatide is approved by the FDA under the brand name Zepbound for chronic weight management and Mounjaro for type 2 diabetes. Compounded tirzepatide is in a legally complex space. The FDA removed tirzepatide from its drug shortage list in late 2024, which affects whether compounded versions can be legally prescribed. Anyone accessing tirzepatide through a medspa should ask directly whether they are receiving brand-name or compounded product, and under what regulatory framework it is being dispensed.
Low-dose or extended-interval maintenance dosing is not an established protocol with published clinical consensus. It may work for some patients. It may not for others. A 2 mg every-two-week dose produces a very different pharmacokinetic profile than the standard weekly dosing studied in trials, and that gap in evidence matters.
If you are considering tirzepatide for reasons beyond its approved indications, including inflammation management or skin conditions, that decision should happen with a physician or NP who is reviewing your full health picture, not someone you booked through a TikTok link.